DUBLIN, December 06, 2021--(BUSINESS WIRE)--The "Rat And Mouse Model Market Size, Share & Trends Analysis Report By Type (Knockout, Knock-in), By Technology, By Service (Breeding, Rederivation), By Application (COVID-19, CVS), By End-use, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
The global rat and mouse model market size is anticipated to reach USD 2.9 billion by 2028, according to a new report by the publisher. The market is expected to expand at a CAGR of 5.5% from 2021 to 2028.
Recent advancements in the field of genetic engineering including piggyBac technologies, Cas-CLOVER, and CRISPR/Cas9 facilitate researchers to develop immunodeficient rat models which can be used for human cell/tissue regeneration and transplants.
Key companies have leveraged advanced technologies such as machine learning, big data analytics, genome engineering tools, and next-generation sequencing technology to develop mouse and rat models with more human-like microbiomes, immune systems, and genetic backgrounds. For instance, models from the Jackson Laboratory reflect the genetic diversity showcased by the human population.
Market participants are focused to develop novel methods to certify that in vivo and in vitro testing complement each other. In this regard, an increase in the adoption rate of organoid systems has been observed. These systems guide engineering as well as enhance the use and selection of animal models. Moreover, the rise in utilization of mouse model in the analysis of SARS-CoV-2 infection in upper and lower respiratory tract infections drives the global market.
Charles River Laboratories, Inc.
The Jackson Laboratory.
Laboratory Corporation of America
Perkin Elmer (Horizon Discovery Group plc)
Taconic Biosciences, Inc.
Biomere (Biomedical Research Models, Inc.)
Transposagen Biopharmaceuticals, Inc.
Rat And Mouse Model Market Report Highlights
The outbred model system generated the largest revenue amongst model type as outbred strains are genetically diverse and feature well-characterized, stable genetic variation which accurately reflects the genetic structure of human populations
Therefore, outbred strains such as the Diversity Outbred (DO) mice are used to analyze the genetic complexity behind cancer, autoimmune disorders, addiction, obesity, heart disease, diabetes, and Alzheimer's disease
The CRISPR/Cas9 segment is anticipated to witness the fastest CAGR from 2021 to 2028 as CRISPR/Cas9 can target any definite exons for exclusion or inclusion within an mRNA
Additionally, the use of the CRISPR/Cas9 system to generate the knockout mouse models simplifies the whole process and reduces the timeframe from 1-2 years to 6 months
The cryopreservation segment is expected to gain significant traction during the forecast period
The technique provides a fast and reliable procedure for archiving sperm and embryos of valuable mice strains
Cancer is the largest revenue-generating application segment as the mouse and human genomes are homologous. Thus, it provides a good tool for cancer research as well as for drug discovery
Pharmaceutical and biotechnology companies dominated the end-use segment in terms of revenue share in 2020. Rat and mice models are some of the most used animal models in drug discovery
Techniques such as CRISPR/Cas9, homologous recombination, and random transgenesis help the biotech and pharma companies to analyze hypotheses or to generate rat models for human diseases
Genetically engineered models play a vital role to assess and characterize target identification, disease pathology, and in vivo assessment of new molecular entities
Profitable opportunities offered by the developing nations and have attracted investments from global companies in the Asia Pacific region
Key Topics Covered:
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Market Variables, Trends & Scope
Chapter 4 Industry Outlook
4.1 Market Variable Analysis
4.1.1 Rise in adoption of personalized medicine and subsequent demand of rat & mouse models for precision medicine approaches
4.1.2 Application of genome editing tools for generation of rodent models
4.1.3 Increase in the number of research activities involving the use of rat and mouse models
4.1.4 Grants & investments
4.2 Market Restraint Analysis
4.2.1 Ethical issues pertaining to the use of animals for research
4.2.2 Rise in adoption of Zebrafish models for biomedical research
4.3 Market Opportunity Analysis
4.3.1 Rise in demand for humanized rat & mouse models
4.3.2 Utility of rat/mouse models to examine the pathogenesis of SARS-CoV-2
4.4 Market Challenge Analysis
4.4.1 Alternatives to Animal Testing
188.8.131.52 In Vitro Testing
184.108.40.206 Computer (in Silico) Modeling
4.4.2 Speculations regarding ban on animal testing
Chapter 5 Business Environment Analysis
5.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
5.2 Porter's Five Forces Analysis
Chapter 6 Competitive Analysis
6.1 Recent Developments & Impact Analysis, by Key Market Participants
6.2 Mergers and acquisitions
6.5 Synergies, Collaborations, and other initiatives
Chapter 7 Type Business Analysis
Chapter 8 Technology Business Analysis
Chapter 9 Service Business Analysis
Chapter 10 Application Business Analysis
Chapter 11 End-use Business Analysis
Chapter 12 Regional Business Analysis
Chapter 13 Company Profile
For more information about this report visit https://www.researchandmarkets.com/r/mf9qqo
View source version on businesswire.com: https://www.businesswire.com/news/home/20211206005522/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900